MorphoSys (MOR) Competitors $18.96 0.00 (0.00%) As of 07/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MOR vs. QGEN, VTRS, ASND, VRNA, BBIO, BPMC, ROIV, LEGN, ELAN, and RGCShould you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include QIAGEN (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Legend Biotech (LEGN), Elanco Animal Health (ELAN), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry. MorphoSys vs. Its Competitors QIAGEN Viatris Ascendis Pharma A/S Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Roivant Sciences Legend Biotech Elanco Animal Health Regencell Bioscience Qiagen (NYSE:QGEN) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Is QGEN or MOR more profitable? Qiagen has a net margin of 4.68% compared to MorphoSys' net margin of -226.79%. Qiagen's return on equity of 14.61% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Qiagen4.68% 14.61% 8.80% MorphoSys -226.79%-694.31%-22.55% Do insiders and institutionals hold more shares of QGEN or MOR? 70.0% of Qiagen shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 0.1% of MorphoSys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer QGEN or MOR? Qiagen presently has a consensus target price of $49.40, indicating a potential downside of 4.62%. Given Qiagen's stronger consensus rating and higher possible upside, equities analysts plainly believe Qiagen is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qiagen 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to QGEN or MOR? In the previous week, Qiagen had 8 more articles in the media than MorphoSys. MarketBeat recorded 8 mentions for Qiagen and 0 mentions for MorphoSys. Qiagen's average media sentiment score of 0.93 beat MorphoSys' score of 0.00 indicating that Qiagen is being referred to more favorably in the media. Company Overall Sentiment Qiagen Positive MorphoSys Neutral Which has higher valuation & earnings, QGEN or MOR? Qiagen has higher revenue and earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQiagen$1.98B5.82$83.59M$0.40129.49MorphoSys$238.28M11.99-$205.35M-$3.48-5.45 Which has more risk and volatility, QGEN or MOR? Qiagen has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. SummaryQiagen beats MorphoSys on 14 of the 16 factors compared between the two stocks. Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOR vs. The Competition Export to ExcelMetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$776.92M$5.70B$9.50BDividend YieldN/A4.84%4.60%4.01%P/E Ratio-5.451.4028.1020.05Price / Sales11.9925.35429.3789.38Price / CashN/A19.5636.2258.56Price / Book54.176.798.665.87Net Income-$205.35M-$4.32M$3.25B$258.55M7 Day PerformanceN/A1.15%4.22%3.73%1 Month PerformanceN/A3.76%10.51%11.75%1 Year Performance2.99%9.52%34.40%18.03% MorphoSys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730QGENQIAGEN3.7199 of 5 stars$48.06-0.6%$49.40+2.8%+26.1%$10.75B$1.98B120.495,765Positive NewsAnalyst DowngradeAnalyst RevisionVTRSViatris2.368 of 5 stars$8.90+0.2%$10.40+16.9%-20.0%$10.42B$14.74B-2.8132,000ASNDAscendis Pharma A/S3.6186 of 5 stars$168.02-1.1%$223.07+32.8%+24.6%$10.39B$393.54M-26.751,017Analyst RevisionVRNAVerona Pharma PLC American Depositary Share2.8275 of 5 stars$104.90flat$109.00+3.9%+375.4%$8.93B$42.28M-52.4530Positive NewsBBIOBridgeBio Pharma4.6357 of 5 stars$45.90-1.3%$61.50+34.0%+73.4%$8.83B$221.90M-13.00400Analyst DowngradeBPMCBlueprint Medicines0.9484 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Positive NewsUpcoming EarningsROIVRoivant Sciences2.649 of 5 stars$11.48+0.3%$16.50+43.7%+7.5%$7.78B$29.05M-45.92860News CoveragePositive NewsInsider TradeLEGNLegend Biotech3.6958 of 5 stars$42.23+1.5%$73.33+73.7%-26.7%$7.64B$627.24M-71.582,609Positive NewsELANElanco Animal Health2.6423 of 5 stars$14.67-0.8%$16.00+9.1%+16.5%$7.34B$4.44B19.829,000News CoverageAnalyst ForecastRGCRegencell Bioscience0.2069 of 5 stars$14.40-0.7%N/AN/A$7.17BN/A0.0010 Related Companies and Tools Related Companies QGEN Competitors VTRS Competitors ASND Competitors VRNA Competitors BBIO Competitors BPMC Competitors ROIV Competitors LEGN Competitors ELAN Competitors RGC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOR) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhat I told my neighbor to do with his moneyWhen a close friend inherited money, Joel Litman gave him the same investment advice he gives his own mom. ...Altimetry | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
